Amphotret (amphotericin B) 50 mg powder for solution for infusion (IV) (Bharat Serums, India) Amphotret (amphotericin B) Deliver medications from Europe within 4-5 days, storage conditions are met, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.
Delivery methods
- EMC post
Delivery time
- 7-10 days
Payment methods
- Payment to Revolut card
- Interchangeable drugs with the same active ingredient:
- Amfolip
- Amphotret
- Fungizome
- Fungison
- Composition
- Active ingredient:1 vial contains 50 mg of amphotericin B;
- Excipients:sodium deoxycholate, diluted phosphoric acid, sodium hydroxide.
- Dosage form
- Lyophilisate for preparation of infusion solution.
- Pharmacological group
- Antifungal agents for systemic use. Antibiotics. ATC code J02A A01.
- readings
- Systemic mycoses candidomycosis, aspergillosis, histoplasmosis, cryptococcosis, coccidioidosis,
- blastomycosis, mucormycosis.
- Treatment of potentially life-threatening fungal infections caused by susceptible species.
- Treatment of American leishmaniasis of the skin and mucous membranes.
- Treatment of patients with persistent fever caused by immune disorders, when previous antibacterial therapy has not produced the desired result.
- Contraindications
- The drug should not be used to treat non-invasive fungal infections.
- The drug is contraindicated in patients with severe kidney, liver, or hematopoietic system diseases, diabetes mellitus, or hypersensitivity to amphotericin B or to any other component included in the dosage form, except in cases where the disease, in the opinion of the doctor, threatens the patient's life, and the pathogen is sensitive only to amphotericin.
- Method of use and dosage
- The drug should be used by slow drip infusion.Intravenous infusion of the drug should be carried out for 2-6 hours, observing the usual measures for intravenous infusions.The recommended concentration for intravenous infusion is 0.1 mg / ml (1 mg / 10 ml). Since the drug is tolerated differently by patients, the dose should be selected and adjusted individually, taking into account the location and intensity of the infection, which is the etiologic factor.
- Treatment usually begins with a daily dose of 0.25 mg / kg body weight, and this dose is administered over 2-6 hours. The first test dose (1 mg in 20 ml of 5% glucose solution), administered intravenously over 20-30 minutes, can be a guideline, although this is not an absolutely reliable method for assessing individual tolerability of the drug. The patient's body temperature, pulse, respiratory rate, and blood pressure should be measured at intervals of 30 minutes for 2-4 hours.
- A patient with a severe and rapidly progressing fungal infection, in the absence of cardiovascular or respiratory disorders, and if he/she has tolerated a test dose without a severe reaction, the drug can be administered intravenously at a dose of 0.3 mg / kg for 2-6 hours. A lower dose, such as 5-10 mg, is recommended for patients with cardiovascular or respiratory disorders with a certain response to the test dose. The dose can be gradually increased from 5-10 mg per day to an average daily dose of -
- 0.5-1 mg / kg. Currently, there is insufficient data based on controlled clinical studies to determine the dose and duration of treatment of patients with various forms of mycoses (e.g. mucormycosis). The optimal dose remains unknown, and the selection of an effective and at the same time sufficiently safe dose is largely carried out empirically. The recommended daily dose may be 1 mg/kg per day or 1.5 mg/kg every other day in case of severe infections caused by fairly resistant pathogens.
- ATTENTION! Under any circumstances, the total daily dose should not exceed 1.5 mg/kg.Overdose of the drug may lead to cardiopulmonary arrest (see the Overdose section).
- The drug is administered intravenously to children from 5 months to 18 years of age. The initial daily dose is 0.25 mg / kg body weight in 5% glucose solution when administered over 6:00. If there are no adverse reactions, the dose can be gradually increased (usually by 0.125-0.25 mg / kg every day or every other day) to a maximum dose of 1 mg / kg of body weight.
- Candidomycosis . For disseminated infections caused byCandida, the usual dose, which ranges from 0.4 to 0.6 mg / kg / day, is used for 4 weeks or more. Depending on the severity of the infection, doses up to 1 mg / kg / day can be used. Treatment is continued until signs of clear clinical improvement appear; adult patients may require total cumulative doses of the drug of 2-4 g. Lower doses (0.3 mg / kg / day) may be needed in special cases, such as esophagitis caused by Candidaresistant to topical treatment, or when the drug is used in combination with other antifungal drugs.
- Cryptococcosis . For treatment of patients without immune system disorders, doses of 0.3 mg/kg/day may usually be needed for approximately 4-6 weeks or until weekly cultures are negative for a month. For patients with immunosuppression, as well as meningitis, the drug can be prescribed in combination with other antifungal agents for 6 weeks.
- Patients with cryptococcal meningitis who have acquired immunodeficiency syndrome (AIDS) may require higher doses (0.7-0.8 mg / kg / day), and courses of treatment can be continued up to
- 12 weeks. For culture-negative AIDS patients after standard treatment, a long-term maintenance dose, such as 1 mg/kg weekly, should be considered.
- Coccidioidomycosis . If treatment of primary coccidioidomycosis is necessary, the drug is administered in doses ranging from
- 1 mg/kg/day to a maximum of 1.5 mg/kg/day are prescribed in cumulative doses - from
- 0.5 to 2.5 g for adults, depending on the severity of the infection and its location. For coccidial meningitis, systemic (intravenous) and intrathecal administration of the drug is possible.
- Blastomycosis . For severe patients with blastomycosis, the drug is recommended to be used in doses of 0.3-1 mg / kg / day in a total cumulative dose, which in adults can range from 1.5 to 2.5 g.
- Histoplasmosis . For chronic pulmonary or disseminated histoplasmosis in adult patients, the usual recommended doses are approximately 0.5 to 1 mg/kg/day for a total cumulative dose of 2-2.5 g.
- Aspergillosis . Aspergillosis was treated with intravenous amphotericin B for 11 months.For the treatment of severe infections, doses of 0.5-1 mg/kg/day or more are required; adults may need cumulative doses of 2-4 g (for example, in pneumonia or the presence of fungal pathogens in the blood). The duration of treatment for severe mycoses can be
- 6-12 weeks or more.
- Rhinocerebral mucormycosis . This active disease usually develops in association with diabetic ketoacidosis. For treatment with amphotericin B to be successful, rapid restoration of the degree of compensation of diabetes mellitus is absolutely necessary. Since rhinocerebral mucormycosis usually leads to a rapid fatal outcome, the therapeutic approach, if necessary, should be more aggressive than for relatively mild mycoses.
- Preparation of solutions.
- Trade Name:Amphotret
- Chemical Name:Amphotericin B
- Dosage:50 mg
- Form of Issue:Ampoule
No reviews yet
